{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 43,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines patient enrollment targets and treatment protocols for specific refractory patient populations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/31",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.34,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "Total patients (n = 40) SCCHN: Prior treatment with a PD-1/L1 inhibitor either administered alone (n = 20) or in combination with Platinum (n = 20) – Q2W Monotherapy Use to determine TmPS cut-off and potential registrational study design",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d0f61e5-8a2c-4090-80a6-52307c3c1504",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.34,
        "x": 0.15,
        "y": 0.38
      },
      "kind": "list",
      "text": "Total patients (n = 100) Melanoma: PD1 failure – (n = 40) Q2W NSCLC: PD1, EGFR or ALK failure – (n = 60) Q2W or 3Q4W Monotherapy and Combination with PD-1/L1 Use to determine TmPS cut-off and potential registrational study design",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f803df1c-934e-4f23-b1a4-8759b4530560",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.14,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Phase 2 – Melanoma / NSCLC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95051f51-b4fd-4d61-9388-e6e67f39342a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.54,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Phase 2 – SCCHN",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b00fde6-f26c-4bd6-96a2-215f377ef912",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: Melanoma, NSCLC and SCCHN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5afcae97-4b73-4059-b1e5-cb2fff0fdd8d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}